|本期目录/Table of Contents|

[1]许庭莹,石大伟,刘东来,等.WHO 对年度优先关注突发传染病的评估方法介绍[J].传染病信息,2019,05:285-389.
 XU Ting-ying,SHI Da-wei,LIU Dong-lai,et al.Introduction of WHO annual assessment methodology for prioritized infectious diseases outbreaks[J].Infectious Disease Information,2019,05:285-389.
点击复制

WHO 对年度优先关注突发传染病的评估方法介绍 (PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2019年05期
页码:
285-389
栏目:
导向与述评
出版日期:
2019-11-13

文章信息/Info

Title:
Introduction of WHO annual assessment methodology for prioritized infectious diseases outbreaks
文章编号:
1007-8134(2019)05-0385-05
作者:
许庭莹石大伟刘东来张春涛
100050北京,中国食品药品检定研究院体外诊断试剂所传染病诊断二室(许庭莹、刘东来、石大伟、张春涛)
Author(s):
XU Ting-ying SHI Da-wei LIU Dong-lai ZHANG Chun-tao*
Division of 2nd In Vitro Diagnostic, National Institute for Food and Drug Control, Beijing 100050, China
关键词:
优先重点关注传染病研究与发展计划优先重点关注传染病清单突发性传染病传染病应急世界卫生组织
Keywords:
priority diseases under the R&D Blueprint list of priority diseases under the R&D Blueprint outbreaks of infectious diseases emergency response to infectious diseases WHO
分类号:
R-013
DOI:
10.3969/j.issn.1007-8134.2019.05.001
文献标识码:
A
摘要:
为完善全球范围内突发传染病的应急处理, WHO作为联合国权威卫生机构,从 2015年 12月开始,召集相关部门和行业专家,对可能引起全球流行性暴发且尚无合理应急预案或应急防治方案不健全的传染性疾病,进行公共卫生流行性风险评估。运用科学的统计评估方法,结合对突发传染病应急处理的经验,制定了优先重点关注传染性疾病研究与发展计划。该计划确定传染病的优先关注顺序标准及该标准的评估方法,发布年度优先重点关注传染病清单。旨在指导各国公共卫生部门、相关科研院所及企业单位加深交流合作,集中优势资源,迅速判断突发疫情发展趋势,高效获得相关病原体诊断试剂、救治药物和防控疫苗产品,快速隔离传染源并实施救治。
Abstract:
As the world authoritative health institutions, WHO has assembled relevant functions and industry experts toconduct a comprehensive assessment to the public health potential transmission risk of the infectious diseases since December 2015,mainly focusing on severe emerging diseases with potential to generate a public health outbreak worldwide, and for which insufficientor no preventive and curative solutions exist. WHO Research and Development Blueprint on prioritized infectious diseases has beenformulated using the scientific methodology for statistics and assessment, and based on experience of emergency response to the outbreak of infectious diseases. This program determines the standard and assessment method for the priority infectious diseases, issues theannual list of infectious diseases prioritized under the Research and Development Blueprint. The program aims to guide public healthdepartments, relevant scientific research institutes and enterprises to deepen the exchange and cooperation, concentrate superiorresources, quickly identify a nascent outbreak, obtain the most advanced products including pathogen’s diagnostic reagents, remedial drugs and control vaccine products, isolate infection source and arrange medical treatment.

参考文献/References

[1] World Health Organization. Ebola: ending the current outbreak,strengthening global preparedness and ensuring WHO’s capacityto prepare for and respond to future large-scale outbreaks andemergencies with health consequences[S]. Geneva: WHO, 2015.
[2] World Health Organization. WHO first consultation on Ebolabiobanking[R]. Geneva: WHO, 2015.
[3] NIPH. Modelling and trial statistics during epidemics[R]. Oslo: NIPH, 2015.
[4] Aysheshim A, Hernando A, Kate A, et al. Managing epidemics: key facts about major deadly diseases[M]. Geneva: WHO, 2018.
[5] NIPH. Financing of R&D preparedness and response to epidemicemergencies[R]. Oslo: NIPH, 2015.
[6] World Health Organization. Developing global norms for sharingdata and results during public health emergencies[R]. Geneva: WHO, 2015.
[7] World Health Organization. Blueprint for R&D preparedness andresponse to public health emergencies due to highly infectiouspathogens[R]. Geneva: WHO, 2015.
[8] World Health Organization. Annual review of diseases prioritizedunder the Research and Development Blueprint[R]. Geneva: WHO, 2018.
[9] World Health Organization. Methodology for prioritizing severeemerging diseases for research and development[R]. Geneva: WHO, 2016.
[10] World Health Organization. Building capacity for material transferagreements in public health emergencies Informal consultation[R]. Institut Pasteur: WHO, 2016.
[11] Ritrovato M, Faggiano FC, Tedesco G, et al. Decision-oriented health technology assessment: one step forward in supporting thedecision-making process in hospitals[J]. Value Health, 2015, 18(4):505-511.
[12] World Health Organization. Country assessments methodology:landscape analysis[EB/OL]. [2019-05-01]. https://www.who.int/nutrition/landscape_analysis/country_assessments/en/.
[13] World Health Organization. WHO countries[EB/OL]. [2019-05?01]. https://www.who.int/countries/en/.
[14] World Health Organization. Annual review of diseases prioritizedunder the Research and Development Blueprint[R]. Geneva: WHO, 2017.
[15] Byers NM, Fleshman AC, Perera R, et al. Metabolomic insights into human arboviral infections: dengue, chikungunya, and Zika viruses[J]. Viruses, 2019, 11(3):pii:e225.
[16] Ganesan VK, Duan B, Reid SP. Chikungunya virus: pathophysiology, mechanism, and modeling[J]. Viruses, 2017, 9(12):pii:e368.
[17] Zhang J, Yan X, Li Y, et al. Reactive plasmacytosis mimickingmultiple myeloma associated with SFTS virus infection: a reportof two cases and literature review[J]. BMC Infect Dis, 2018, 18(1):528.
[18] Oh HS, Kim M, Lee JO, et al. Hemophagocytic lymphohistiocytosis associated with SFTS virus infection: a case report with literaturereview[J]. Medicine (Baltimore), 2016, 95(31):e4476.
[19] World Health Organization. Target product profile for multivalentfilovirus vaccines: providing long-term protection to high-riskpopulations [R]. Geneva: WHO, 2016.
[20] World Health Organization. Global consultation on research related to zika virus infection[R]. Geneva: WHO, 2016.
[21] Modjarrad K, Moorthy VS, Ben Embarek P, et al. A roadmap forMERS-CoV research and product development: report from aWorld Health Organization consultation[J]. Nat Med, 2016, 22(7):701-705.
[22] Panda S, Swaminathan S, Hyder KA, et al. Drug resistance inmalaria, tuberculosis, and HIV in South East Asia: biology,programme, and policy considerations[J]. BMJ, 2017, 358:j3545.
[23] 刘东来,张春涛 . 重大病毒疫情与诊断试剂[J]. 传染病信息, 2019,32(1):21-25.
[24] Nickol ME, Kindrachuk J. A year of terror and a century ofreflection: perspectives on the great influenza pandemic of 1918?1919[J]. BMC Infect Dis, 2019, 19(1):117.
[25] Humphreys M. The influenza of 1918: evolutionary perspectivesin a historical context[J]. Evol Med Public Health, 2018, 2018(1):219-229.
[26] Jester B, Uyeki TM, Jerniqan DB, et al. Historical and clinical aspects of the 1918 H1N1 pandemic in the United States[J]. Virology, 2019, 527:32-37.
[27] Escudero JA, Mazel D. Genomic plasticity of vibrio cholerae[J]. Int Microbiol, 2017, 20(3):138-148.
[28] Fenollar F, Mediannikov O. Emerging infectious diseases inAfrica in the 21st century[J]. New Microbes New Infect, 2018, 26(Suppl 1):S10-S18.
[29] Davies HG, Bowman C, Luby SP. Cholera-management andprevention[J]. J Infect, 2017, 74(Suppl 1):S66-S73.

备注/Memo

备注/Memo:
[基金项目]国家科技重大专项(2018ZX10102001)
[作者单位]100050北京,中国食品药品检定研究院体外诊断试剂所传染病诊断二室(许庭莹、刘东来、石大伟、张春涛)
[通信作者]张春涛,E-mail:zhangct2@126.com*
Correspondingauthor,E-mail:zhangct2@126.com
更新日期/Last Update: 2019-11-13